|
gptkbp:instanceOf
|
gptkb:company
|
|
gptkbp:awards
|
gptkb:Fierce_15_(FierceBiotech,_2017)
|
|
gptkbp:CEO
|
gptkb:Mike_Nolan
|
|
gptkbp:clinicalTrialPhase
|
gptkb:PREEMPT_CRC
|
|
gptkbp:collaboratesWith
|
gptkb:National_Cancer_Institute
gptkb:American_Cancer_Society
gptkb:Exact_Sciences
|
|
gptkbp:focusesOn
|
liquid biopsy
early cancer detection
|
|
gptkbp:foundedYear
|
2014
|
|
gptkbp:founder
|
gptkb:Gabe_Otte
gptkb:Randy_Scott
gptkb:Charles_Roberts
gptkb:Michael_Otte
|
|
gptkbp:headquartersLocation
|
gptkb:South_San_Francisco,_California,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Freenome
|
|
gptkbp:industry
|
gptkb:biotechnology
healthcare
|
|
gptkbp:mission
|
empower everyone to prevent, detect, and treat disease
|
|
gptkbp:notableInvestment
|
gptkb:Perceptive_Advisors
gptkb:RA_Capital_Management
gptkb:Andreessen_Horowitz
gptkb:Polaris_Partners
gptkb:Reinvent_Capital
gptkb:Google_Ventures
gptkb:Roche
Section 32
Fidelity
|
|
gptkbp:numberOfEmployees
|
over 300 (as of 2023)
|
|
gptkbp:product
|
multiomics blood test
|
|
gptkbp:regulates
|
in clinical trials (as of 2023)
|
|
gptkbp:technology
|
gptkb:machine_learning
genomics
|
|
gptkbp:valuation
|
over $2.5 billion (as of 2023)
|
|
gptkbp:website
|
https://www.freenome.com/
|
|
gptkbp:bfsParent
|
gptkb:Fabrice_Grinda
gptkb:Casdin_Capital
gptkb:Martin_Casado
gptkb:Scott_Kupor
|
|
gptkbp:bfsLayer
|
6
|